Political drive to screen for pre-dementia: Not evidence based and ignores the harms of diagnosis

BMJ (Online)

Volumn 347, Issue 7925, 2013, Pages

  Le Couteur, David G ^a   Doust, Jenny ^b   Creasey, Helen ^c   Brayne, Carol ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BOND UNIVERSITY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; GINKGO BILOBA EXTRACT; MEMANTINE;

AGE; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL PRACTICE; DEMENTIA; DSM-5; EARLY DIAGNOSIS; FAINTNESS; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HIP FRACTURE; HUMAN; LIFESTYLE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; UNITED KINGDOM; UNITED STATES;

BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FUNCTIONAL NEUROIMAGING; GREAT BRITAIN; HEALTH POLICY; HUMANS; MASS SCREENING; MILD COGNITIVE IMPAIRMENT; POLITICS;

EID: 84884790881     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5125     Document Type: Article

References (73)

1. Department of Health. Policy improving care for people with dementia. 2013. www.gov. uk/government/policies/improving-care-for-people-with-dementia.
2. Chinthapalli K. Reward doctors for early diagnosis of dementia, says think tank. BMJ 2012;345:e8533.
3. Lind S. DH asks GPs to design alternative to dementia DES. Pulse 2013 Jan 24. www.pulsetoday.co.uk/home/gp-contract-2013/14/dh-asks-gps-to-design- alternative-to-dementiades/20001599.article#.UZFfeJEs9nU.
4. Naylor MD, Karlawish JH, Arnold SE, Khachaturian AS, Khachaturian ZS, Lee VM, et al. Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware invitational summit. Alzheimers Dement 2012;8:445-52.
5. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-31.
6. Connolly A, Gaehl E, Martin H, Morris J, Purandare N. Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence. Aging Ment Health 2011;15:978-84.
7. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet 2012;380:1441-3.
8. Richards M, Brayne C. What do we mean by Alzheimer's disease? BMJ 2010;341:c4670.
9. Ashford JW, Borson S, O'Hara R, Dash P, Frank L, Robert P, et al. Should older adults be screened for dementia? Alzheimers Dement 2006;2:76-85.
10. Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin PJ, et al. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement 2013;9:151-9.
11. Kmietowicz Z. Cameron launches challenge to end "national crisis" of poor dementia care. BMJ 2012;344:e2347.
12. Eaton J. Every town and city in England is to have a memory clinic by 2011. BMJ 2009;338:b464.
13. Coombes R. Evidence lacking for memory clinics to tackle dementia. BMJ 2009;338:375.
14. Lindesay J, Marudkar M, van Diepen E, Wilcock G. The second Leicester survey of memory clinics in the British Isles. Int J Geriatr Psychiatry 2002;17:41-7. (Pubitemid 34121095)
15. O'Brien JT, Burns A, Group BAPDC. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:997-1019.
16. Manthorpe J, Samsi K, Campbell S, Abley C, Keady J, Bond J, et al. From forgetfulness to dementia: clinical and commissioning implications of diagnostic experiences. Br J Gen Pract 2013;63:69-75.
17. Rosness TA, Ulstein I, Engedal K. Stress affects carers before patient's first visit to a memory clinic. Int J Geriatr Psychiatry 2009;24:1143-50.
18. Spies PE, Slats D, Ramakers I, Verhey FR, Olde Rikkert MG. Experiences with cerebrospinal fluid analysis in Dutch memory clinics. Eur J Neurol 2011;18:1014-6.
19. Braekhus A, Ulstein I, Wyller TB, Engedal K. The memory clinic-outpatient assessment when dementia is suspected. Tidsskr Nor Laegeforen 2011;131:2254-7.
20. Meeuwsen EJ, Melis RJ, Van Der Aa GC, Goluke-Willemse GA, De Leest BJ, Van Raak FH, et al. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial. BMJ 2012;344:e3086.
21. Wilson JMG, Jungner G. The principles and practice of screening for disease. World Health Organization, 1968.
22. Brunet MD, McCartney M, Heath I, Tomlinson J, Gordon P, Cosgrove J, et al. There is no evidence base for proposed dementia screening. BMJ 2012;345:e8588.
23. UK National Screening Committee. The UK NSC policy on Alzheimer's disease screening in adults. 2010. www.screening.nhs.uk/alzheimers.
24. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 8th ed. RACGP, 2012.
25. US Preventive Services Task Force. Screening for dementia. 2003. www.uspreventiveservicestaskforce.org/uspstf/uspsdeme.htm.
26. Corbyn Z. New set of Alzheimer's trials focus on prevention. Lancet 2013;381:614-5.
27. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92.
28. Lopez OL, McDade E, Riverol M, Becker JT. Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol 2011;24:532-41.
29. Stephan BC, Brayne C, McKeith IG, Bond J, Matthews FE. Mild cognitive impairment in the older population: who is missed and does it matter? Int J Geriatr Psychiatry 2008;23:863-71.
30. Ritchie LJ, Tuokko H. Mild cognitive impairment: case definitions, age, and other risk factors. In: Stone JH, Blouin M, eds. International encyclopedia of rehabilitation. 2013. http://cirrie.buffalo.edu/encyclopedia/en/article/117/.
31. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
32. Dubois B, Gauthier S, Cummings J. The utility of the new research diagnostic criteria for Alzheimer's disease. Int Psychogeriatr 2013;25:175-7.
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed.APA, 2013.
34. Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement 2012;8:14-21.
35. Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry 2008;79:1386-91.
36. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252-65.
37. Song X, Mitnitski A, Zhang N, Chen W, Rockwood K. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative. J Neurol Neurosurg Psychiatry 2013;84:71-8.
38. Stephan BC, Hunter S, Harris D, Llewellyn DJ, Siervo M, Matthews FE, et al. The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry 2012;17:1056-76.
39. Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, et al. The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurol 2013;70:1-8.
40. Flicker LA, Ford AH, Beer CD, Almeida OP. Memory loss. Med J Aust 2012;196:114-7.
41. Mitchell AJ, Meader N, Pentzek M. Clinical recognition of dementia and cognitive impairment in primary care: a meta-analysis of physician accuracy. Acta Psychiatr Scand 2011;124:165-83.
42. Wharton SB, Brayne C, Savva GM, Matthews FE, Forster G, Simpson J, et al. Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. J Alzheimers Dis 2011;25:359-72.
43. Neuropathology Group of the Medical Research Council. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-75.
44. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013;9:54-8.
45. Carrillo MC, Bain LJ, Frisoni GB, Weiner MW. Worldwide Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2012;8:337-42.
46. Knopman DS. Alzheimer disease biomarkers and insights into mild cognitive impairment. Neurology (forthcoming).
47. Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement 2013;9:e96-105.
48. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012;78:468-76.
49. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
50. Schneider LS. Quantifying and amyloid beta model for Alzheimers disease. Lancet Neurology 2013;22:327-8.
51. Prince M, Bryce R, Ferri C. World Alzheimer report 2011. The benefits of early diagnosis and intervention. www.alz.co.uk/worldreport2011.
52. Waldorff FB, Buss DV, Eckermann A, Rasmussen ML, Keiding N, Rishoj S, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ 2012;345:e4693.
53. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007;21:217-30. (Pubitemid 46804936)
54. Masoodi N. Review: cholinesterase inhibitors do not reduce progression to dementia from mild cognitive impairment. Ann Intern Med 2013;158:JC2-3.
55. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009;169:867-73.
56. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35.
57. Le Couteur DG, Robinson M, Leverton A, Creasey H, Waite L, Atkins K, et al. Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australas J Ageing 2012;31:164-9.
58. Wimo A, Religa D, Spangberg K, Edlund AK, Winblad B, Eriksdotter M. Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry. Int J Geriatr Psychiatry 2013 Feb 26. [Epub ahead of print.]
59. Bunn F, Goodman C, Sworn K, Rait G, Brayne C, Robinson L, et al. Psychosocial factors that shape patient and carer experiences of dementia diagnosis and treatment: a systematic review of qualitative studies. PLoS Med 2012;9:e1001331.
60. Draper B, Peisah C, Snowdon J, Brodaty H. Early dementia diagnosis and the risk of suicide and euthanasia. Alzheimers Dement 2010;6:75-82.
61. Brayne C, Gao L, Dewey M, Matthews FE. Dementia before death in ageing societies-the promise of prevention and the reality. PLoS Med 2006;3:e397.
62. Brunet MD. Early diagnosis of dementia-cui bono? 2012. http://binscombe.net/blog/? p=464.
63. Cambridge Cognition. NHS Commissioning Board sets out new DES for dementia. Press release, 19 April 2013. www.cambridgecognition.com/news-item. asp?$=42&o=.
64. Social Market Foundation. Think tank calls for financial rewards for increased dementia diagnosis rates. 2012. www.smf.co.uk/media/news/think-tank- calls-for-financial-rewardsfor-increased-dementia-di/.
65. Meulen EF, Schmand B, van Campen JP, de Koning SJ, Ponds RW, Scheltens P, et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004;75:700-5. (Pubitemid 38526679)
66. Senior PsychCare. Early diagnosis: The 7 minute Alzheimer's test. 2013. www.seniorpsychiatry.com/articles/7min-alz-test.html.
67. Mitka M. PET imaging for Alzheimer disease: are its benefits worth the cost? JAMA 2013;309:1099-100.
68. Cambridge Cognition. CANTABmobile. www.cantabmobile.com.
69. Lane HP, McLachlan S, Philip J. The war against dementia: are we battle weary yet? Age Ageing 2013;42:281-3.
70. Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ, Fultz BA, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med 2005;20:572-7. (Pubitemid 41026239)
71. Boustani M, Perkins AJ, Monahan P, Fox C, Watson L, Hopkins J, et al. Measuring primary care patients' attitudes about dementia screening. Int J Geriatr Psychiatry 2008;23:812-20.
72. Justiss MD, Boustani M, Fox C, Katona C, Perkins AJ, Healey PJ, et al. Patients' attitudes of dementia screening across the Atlantic. Int J Geriatr Psychiatry 2009;24:632-7.
73. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011;10:819-28.